Changfeng Pharmaceutical: Clinical trial application for Loratadine Mometasone Nasal Spray accepted by NMPA.

Changfeng Pharmaceutical announced that the group has successfully submitted a clinical trial application for its independently developed fixed-dose combination formulation of Olopatadine and mometasone nasal spray, and has received an acceptance notification from the China National Medical Products Administration.